Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01361048 · ClinicalTrials.gov registry record · Phase 2
Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01361048 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 40 participants.
The verdict
NCT01361048, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The investigators are trying a combination vaginal product of higher dose metronidazole combined with miconazole to see if it is effective in treating vaginal trichomonas.
Interventions
- DRUG oral metronidazole
- DRUG neo penotran forte
- DRUG neo penotran forte once a day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01361048
The ClinicalTrials.gov registry entry for NCT01361048 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which oral metronidazole is the first listed.
NCT01361048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01361048 about?
NCT01361048 is a clinical study titled "Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis". The investigators are trying a combination vaginal product of higher dose metronidazole combined with miconazole to see if it is effective in treating vaginal trichomonas.
What is the current status of trial NCT01361048?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2011-12. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01361048?
The interventions under investigation include: oral metronidazole (DRUG), neo penotran forte (DRUG), neo penotran forte once a day (DRUG).
Who is sponsoring clinical trial NCT01361048?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.